Eli Lilly's GLP-1 Drug Development and Market Strategy

This case study explores the promising potential of GLP-1 drugs, including tirzepatide and Orforglipron, in treating obesity and related comorbidities. Insights from Eli Lilly's leadership highlight the company's strategic investments and capacity expansion plans aimed at addressing market demand. The document discusses the implications of these developments for the pharmaceutical industry and the anticipated impact of innovative oral medications on healthcare systems worldwide.